Insider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Sells 400 Shares of Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch sold 400 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $60.00, for a total value of $24,000.00. Following the completion of the sale, the director now owns 130,544 shares of the company’s stock, valued at approximately $7,832,640. The trade was a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Lynch also recently made the following trade(s):

• On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $54.46, for a total value of $9,530,500.00.

SpringWorks Therapeutics Trading Down 2.7 %

NASDAQ SWTX opened at $58.29 on Friday. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $62.00. The stock has a fifty day simple moving average of $41.10 and a 200-day simple moving average of $37.64.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $61.55 million for the quarter, compared to analysts’ expectations of $60.53 million. As a group, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On SpringWorks Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Huntington National Bank boosted its holdings in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after acquiring an additional 192 shares during the period. AlphaQuest LLC boosted its holdings in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after acquiring an additional 414 shares during the period. Venturi Wealth Management LLC purchased a new position in SpringWorks Therapeutics during the 4th quarter valued at about $45,000. State of Wyoming boosted its holdings in SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after acquiring an additional 433 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in SpringWorks Therapeutics during the 4th quarter valued at about $56,000.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SWTX shares. Wedbush restated an “outperform” rating and issued a $81.00 target price on shares of SpringWorks Therapeutics in a report on Thursday. Guggenheim lowered their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a report on Friday. Finally, Evercore ISI increased their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $71.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.